Tuberculosis remains the world's leading cause of death from an infectious disease,
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …

Abstract Drug-resistant TB (DR-TB) remains a significant challenge in TB treatment and
control programmes worldwide. Advances in sequencing technology have significantly …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …

Executive summary Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult
to treat than drug-susceptible ones, and threaten global progress towards the targets set by …

Page 1 WHO Module 4: Treatment Drug-susceptible tuberculosis treatment operational
handbook on tuberculosis World Health Organization Page 2 WHO operationa handbook …

Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America …

The “WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis-Rapid diagnostics
for tuberculosis detection, third edition” is the latest document replacing the one issued in …

Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to
rifampicin and other TB medicines challenge patient survival and public health. The World …

Between 2011 and 2019, WHO has developed and issued evidence-based policy
recommendations on the treatment and care of patients with DR-TB. These policy …

Whole genome sequencing (WGS) of Mycobacterium tuberculosis has rapidly progressed
from a research tool to a clinical application for the diagnosis and management of …